• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Companion Medical wins FDA nod for InPen diabetes management system

February 28, 2020 By Sean Whooley

Companion MedicalCompanion Medical announced that it won FDA clearance for its InPen bolus calculator for fixed dosing and meal estimation in diabetes management.

The new bolus calculator is designed to account for the user’s current glucose level and active insulin to remove the guesswork from insulin dosing. Companion Medical touts the system as the first of its kind to win clearance for those with Type 1 or Type 2 insulin-dependent diabetes who administer a fixed amount of insulin for meals or deliver a dose based on the approximate size of their planned meal.

San Dieg–-based Companion Medical’s InPen includes a smartpen and a Bluetooth-connected app. Altogether, is designed to help calculate insulin doses, track active insulin and send reports to caregivers. The platform is available in the U.S. by prescription only, while the app is available for download through the Apple App Store and Google Play, according to a news release.

Janice MacLeod, who leads Companion Medical’s clinical advocacy efforts, said in the news release that the InPen platform offers a new option to patients who aren’t able to or would not like to count carbs for every meal, while it helps avoid stacking insulin and it minimizes the risk of low glucose.

“Our goal since launching in 2017 has been to make insulin therapy simpler for all people with diabetes – not just the most engaged or advanced,” Companion Medical founder & CEO Sean Saint said in the release. “We do this by letting the InPen system do most of the heavy lifting and ease the burden. Similar to the first InPen dose calculator, which has been a game-changer for those of us who count carbs, this new FDA clearance for users on fixed-dose or meal estimation therapy finally offers a simple, yet advanced solution to those people living with insulin-dependent diabetes who are not expert carb counters.”

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance Tagged With: Companion Medical, FDA

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS